CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 7 enrolled
Drug / intervention
Reserpinedrug
Likely dose
Reserpine 0.1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03223272
NCT03223272Phase 2Completed
CompareCT.gov

Mechanisms of Refractory Hypertension (Reserpine)

University of Alabama at Birmingham·interventional·Posted Jul 21, 2017·Updated Nov 30, 2021

In Brief

A Phase 2 clinical trial evaluating Reserpine for Refractory Hypertension. Completed, enrolled 7 participants across 1 site.

Detailed Summary

The study is deigned to determine if refractory hypertension is attributable to heightened sympathetic tone by quantifying the antihypertensive benefit of reserpine, a sympatholytic agent, in patients failing other classes of antihypertensive agents.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Hypertension
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 21, 2017
Enrollment StartJul 23, 2015
Primary CompletionJan 31, 2020
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 8.9 years ago

Interventions

Reserpinedrug

Open label reserpine 0.1 mg pill orally